Search - tctmd.com

Displaying 101 - 120 of 437

Sort: Relevancy | Date

News Conference News EuroPCR 2018

Balking at Bulk: SORT-OUT VIII Hints at Clinical Edge for Thinner-Strut Stents

Shelley Wood

May 24, 2018

News Industry News

Positive Two-Year Data from MiStent® DESSOLVE III Trial Presented at EuroPCR

May 24, 2018

News Industry News

Micell Technologies Announces Expanded Patent Estate - Issued Key Patents Significantly Strengthen Company’s Proprietary Rights in Surface Modification and Controlled Drug Delivery

March 21, 2018

News Conference News CRT 2018

Wait Continues for a Win With Biodegradable-Polymer DES in Patients at High Bleeding Risk: BIO-RESORT

Michael O'Riordan

March 08, 2018

News Industry News

REVA Announces CE Mark and First Implant of the Fantom Encore Bioresorbable Scaffold

February 26, 2018

News Industry News

SELUTION™ First-in-Man Study Achieves Primary Endpoint

January 31, 2018

News Industry News

Positive Five-Year Data Published for MiStent in EuroIntervention

January 12, 2018

News Industry News

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

December 06, 2017

News Conference News TCT 2017

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

Todd Neale

November 01, 2017

News Conference News ESC 2017

BIOFLOW V: ‘Ultrathin-Strut’ Stent Beats Out Xience at 12 Months

Shelley Wood

August 30, 2017

News Industry News

STENTYS Completes Enrollment in the Study Assessing the Safety and Efficacy of Xposition S in Left Main Artery Lesions

July 28, 2017

News Features EuroPCR 2017

Seven Next-Generation Bioresorbable Scaffolds Show Promise but Face Major Hurdles

Yael L. Maxwell

June 01, 2017

News Industry News

STENTYS: Follow-Up of the APPOSITION IV and OPEN II Clinical Trials at Respectively 3 and 4 Years Confirms the Initial Positive Study Outcomes

May 25, 2017

News Conference News EuroPCR 2017

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Michael O'Riordan

May 18, 2017

News Industry News

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

May 16, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Conference News EuroPCR 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Shelley Wood

May 12, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ISET 2017

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

Caitlin E. Cox

February 17, 2017

News Daily News

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

L.A. McKeown

February 08, 2017

Advertisement

Balking at Bulk: SORT-OUT VIII Hints at Clinical Edge for Thinner-Strut Stents

Positive Two-Year Data from MiStent® DESSOLVE III Trial Presented at EuroPCR

Micell Technologies Announces Expanded Patent Estate - Issued Key Patents Significantly Strengthen Company’s Proprietary Rights in Surface Modification and Controlled Drug Delivery

Wait Continues for a Win With Biodegradable-Polymer DES in Patients at High Bleeding Risk: BIO-RESORT

REVA Announces CE Mark and First Implant of the Fantom Encore Bioresorbable Scaffold

SELUTION™ First-in-Man Study Achieves Primary Endpoint

Positive Five-Year Data Published for MiStent in EuroIntervention

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

BIOFLOW V: ‘Ultrathin-Strut’ Stent Beats Out Xience at 12 Months

STENTYS Completes Enrollment in the Study Assessing the Safety and Efficacy of Xposition S in Left Main Artery Lesions

Seven Next-Generation Bioresorbable Scaffolds Show Promise but Face Major Hurdles

STENTYS: Follow-Up of the APPOSITION IV and OPEN II Clinical Trials at Respectively 3 and 4 Years Confirms the Initial Positive Study Outcomes

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content